Home
About Us
About Boan
Culture
Our History
Our Team
Responsibility
R&D
Technology platform
Boan Product Pipeline
Intellectual Property
Production capacity
Products
News
Careers
People Strategy
Employee Stories
Development
Job Opportunities
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Contact us
简
/
繁
/
EN
News
Year
2021
2022
2023
2024
2025
Month
1
2
3
4
5
6
7
8
9
10
11
12
2025.12.10
Boan Biotech Grants NKF Exclusive Rights to Commercialize Two Denosumab Drugs in the US
2025.11.26
Boan Biotech’s Boyoujing
®
Approved for Marketing in China for the Treatment of nAMD and DME
2025.11.07
Marketing Authorization Applications for Boan Biotech’s Two Denosumab Injections Accepted in the UK
31
2025-10
BA1104 Phase III Trial in China Completes Patient Enrollment
20
2025-10
Boan Biotech Presents Early Findings about BA1301 at ESMO 2025
28
2025-08
Boan Biotech Announces 2025 Half-Year Results
08
2025-08
Boyouping®, China’s First Locally Developed Dulaglutide Injection, Approved for Marketing
15
2025-07
Dr. Changlin Dou Appointed IFPMA ICH M18 Task Force Lead Expert
17
2025-06
Boan Receives FDA IND Clearance for Its CD228-Directed ADC
12
2025-06
Boan Grants Shaphar Right to Commercialize BA5101 in China
1
2
3
4
5
Follow me
鲁公网安备37069102000284
ICP备：鲁ICP备2021004064号-1
